

<b>Date and Time:</b>	<b>12<sup>th</sup> March 2013; 10.30 – 16.30hrs</b>
-----------------------	---

<b>Minutes:</b>		
<b>Guideline Development Group Meeting</b>		
<b>Place:</b>	<i>NCGC Boardroom, Great Portland Street, London</i>	
<b>Present:</b>	<p>Philip Conaghan (Chair)            Mark Porcheret (MP)            Ian Bernstein (IB)            Fraser Birrell (FB)            Michael Doherty (MD)            Rob Middleton (RM)            Krysia Dziedzic (KD)            Weiya Zhang (WZ)            Tony Whiting (TW)            Erika Baker (EB)            Brian Lucas (BL)            Jo Cumming (JC)</p> <p>Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN)            Emmert Roberts, Research Fellow (ER)            Margaret Constanti, Health Economist (MC)            Sue Latchem, Guideline Lead and Operations Director (SL)</p>	
<b>Apologies</b> Peter Kay Richard Frearson Elspeth Wise		
<b>NICE</b> Ben Doak		

**Declarations of Interest**

**WZ**

Declared a personal non-specific pecuniary interest:  
 WZ will chair a panel discussion about topical NSAIDs in OA at EULAR 2013, Madrid, 12-15 June. The meeting will be sponsored by Daiichi Sankyo (which produces loxoprofen both oral and patch products). WZ's travel, hotel expense and honorarium (1000 euros) will be covered. WZ may withdraw from GDG discussions whenever topical NSAIDs are discussed (as a comparator as we are not looking at them as part of the scope).

Declared a personal specific pecuniary interest:

WZ will present the clinical practice guidelines of OA (CG59) in the Peking University OA International Forum, Beijing 6-8 Sept 2013. WZ's travel, hotel and honorarium will be paid.

**KD**

Declared personal non-pecuniary interests:

KD will attend the Oxford University Evidence Live conference on the 25<sup>th</sup> March and will attend the British Society for Rheumatology OA Special Interest Group OA Trial Bank talk and will facilitate a workshop hand OA.

**MP**

Declared a personal non-pecuniary interest:

MP has been asked to join the review panel for the knee OA options grid. The Option Grid Collaborative is not for profit and operates under a Creative Commons License. The value of these tools was clear during the MAGIC Programme (Health Foundation) on how best to do shared decision making in the NHS (2010-2012).

**RM**

Declared a personal non-pecuniary interest:

RM gave a lecture to patient group on the prevention and treatment of OA.

Declared a personal non-specific pecuniary interest:

RM is also the director of a consultancy that provides DVT devices.

**JC**

Declared a personal pecuniary interest:

Received funding from Arthritis Care to attend the next EULAR meeting.

No further actions were taken following these declarations other than those outlined above where relevant

1. Philip Conaghan welcomed the group to the ninth meeting of this GDG. PC asked the GDG for any new DOIs since GDG meeting 1.

2. Margaret Constanti presented the work in progress for the OA modelling.

3. Emmert Roberts presented the evidence reviewed (and any new studies from the first re-run searches) so far for the following clinical areas:

- Diagnosis
- Etoricoxib 30mg
- NSAIDS+GPA
- Patient review
- Decision aids
- Acupuncture
- Nutraceuticals
- Hyaluronan injections

-Paracetamol

Margaret Constanti presented any economic studies retrieved as part of the above clinical areas. The GDG agreed changes to previously drafted recommendations and developed further new recommendations.

4. Vanessa Delgado Nunes presented the recommendations contained in CG59 with a view to agree with the GDG which would have to be removed/revised as part of this guideline update.
5. Vanessa Delgado Nunes discussed with the GDG some issues arising from the preliminary sift of the literature for the evidence review on the consideration of timing for referral to surgery.
6. Philip Conaghan asked the GDG whether there were any items under AOB and closed the meeting at 16.45hrs.

**Date, time and venue of the next meeting**

1<sup>st</sup> May 2013, 10:30 – 16:30hrs.